1-15. (canceled)
16. A method for transmitting data having multimedia contents from a first communications unit to a second communications unit in a telecommunications network, the method comprising:
transmitting at least one transmission status message assigned to the data to the first communications unit; and
providing, upon non-deliverability of the data to the second communications unit, an item of information concerning the non-deliverability of the transmitted data in the transmission status message;
wherein the non-deliverability of the data sent applies if one of the correct receipt of the data sent and a recipient notification message concerning the data to be transmitted to the second communications unit is not acknowledged by the second communications unit via a respectively associated confirmation message.
17. A method for transmitting data as claimed in claim 16, wherein the item of information concerning the non-deliverability of the data sent is provided in the transmission status message if the data cannot be delivered to the second communications unit within the definable period of validity.
18. A method for transmitting data as claimed in claim 16, wherein the non-deliverability of the data sent applies if the correct receipt of the data sent and of a recipient notification message concerning the data to be transmitted to the second communications unit is not acknowledge by the second communications unit via a respectively associated confirmation message.
19. A method for transmitting data as claimed in claim 16, wherein the telecommunications network includes a switching arrangement via which the data is transmitted from the first communications unit to the second communications unit, and wherein the switching arrangement establishes the non-deliverability of the data sent and sends the transmission status message to the first communications unit.
20. A method for transmitting data as claimed in claim 16, wherein the data is transmitted via a Multimedia Messaging Service by using a Wireless Application Protocol.
21. A method for transmitting data as claimed in claim 20, wherein the recipient notification message includes a Multimedia Messaging Service message in a category \u201cX-Mms-Message-Type: m-notification-ind.\u201d
22. A method for transmitting data as claimed in claim 20, wherein the data is transmitted to the recipient via at least one Multimedia Messaging Service message in a category \u201cX-Mms-Message-Type: m-retrieve-conf.\u201d
23. A method for transmitting data as claimed in claim 20, wherein the transmission status message includes a Multimedia Messaging Service message in a category \u201cX-Mms-Message-Type: m-delivery-ind.\u201d
24. A method for transmitting data as claimed in claim 23, wherein the item of information concerning the non-deliverability of the data set is represented by the value \u201c<Octet 133>\u201d in the data field \u201cX-Mms-Status\u201d of the transmission status message.
25. A method for transmitting data as claimed in claim 16, wherein at least one of the first communications unit and the second communications unit is a mobile communication module.
26. A method for transmitting data as claimed in claim 16, wherein the telecommunications network is mobile communication network and at least one of the first communications unit and second communications unit operate as defined by a standard which is at least one of GSM, GPRS, EDGE and UMTS.
27. A switching arrangement for transmitting data in a telecommunications network from a first communications unit to a second communications unit, comprising an apparatus for producing a transmission status message which is assigned to the data to be transmitted to the second communications unit, the apparatus providing an item of information concerning non-deliverability of the data to be transmitted in the transmission status message if the data cannot be delivered to the second communications unit and, with regard to the apparatus for producing the transmission status message, non-deliverability of the data sent applies if one of the correct receipt of the data sent and a recipient notification message concerning the data to be transmitted to the second communications unit is not acknowledged by the second communication unit via a respectively associated confirmation message.
28. A switching arrangement as claimed in claim 27, wherein the apparatus for producing the transmission status message provides the item of information concerning the non-deliverability of the data to be transmitted in the transmission status message if the data cannot be delivered to the second communications unit within a definable period of validity.
29. A switching arrangement as claimed in claim 27, wherein the non-deliverability of the data sent applies if the correct receipt of the data sent and of a recipient notification message concerning the data to be transmitted to the second communications unit is not acknowledged by the second communications unit via a respectively associated confirmation message.
30. A switching arrangement as claimed in claim 27, further comprising an apparatus for transmitted the transmission status message to the first communications unit.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula (I)
or a therapeutically acceptable salt, wherein
A is selected from the group consisting of
\u2003wherein the dotted line is either absent or is a single bond;
B is selected from the group consisting of hydrogen, alkyl, aryl, arylalkyl,
D is selected from the group consisting of
wherein Z is selected from the group consisting of alkoxy, alkyl, amino, cyano, nitro, CO2P1, SO3H, PO(OH)2, CH2PO(OH)2, CHFPO(OH)2, CF2PO(OH)2, and C(\u2550NH)NH2;
wherein P1 and P2 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkyl, cycloalkyl and (cycloalkyl)alkyl;
R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, alkoxy, alkyl, aryl, arylalkyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, nitro, NRARB, NRARBC(O), NRARBC(O)alkyl and NRARBC(O)alkenyl, wherein RA and RB are independently selected from the group consisting of hydrogen, alkyl, alkoxycarbonyl, alkylsulfonyl, aryl, arylalkylcarbonyl, arylcarbonyl, arylsulfonyl and (RCRDN)carbonyl wherein RC and RD are independently selected from the group consisting of hydrogen, alkyl, aryl, and arylalkyl;
L is selected from the group consisting of \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014; \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pEC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014; \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014; \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3(CH2)qX4\u2014; and \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pE(CH2)qX3\u2014, wherein each group is drawn with the left end attached to A and the right end attached to B;
m, n, p and q are independently between 0-4;
R8 is selected from the group consisting of hydrogen, hydroxy, NRARB and (NRARB)alkyl;
R9A and R9B are independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl and RERFNalkyl, wherein RE and RF are independently selected from the group consisting of hydrogen, alkyl, alkoxycarbonyl and alkanoyl, or R9A and R9B taken together are oxo;
R10 is selected from the group consisting of hydrogen, alkyl, alkanoyl and alkoxycarbonyl;
R11 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkyl, cycloalkyl, and (cycloalkyl)alkyl;
E is selected from the group consisting of aryl and cycloalkyl;
X1, X2, X3, and X4 are independently absent or are independently selected from the group consisting of NRG, O, S, S(O) and S(O)2, wherein RG is selected from the group consisting of hydrogen, alkyl, alkanoyl and alkoxycarbonyl; and
W1, W2, W3 and W4 are independently selected from the group consisting of CH, CH2, N, NH and O.
2. The compound according to claim 1 of formula (II)
or a therapeutically acceptable salt wherein A, B, L, P1, P2, R1, R2, and R3 are defined in claim 1.
3. The compound according to claim 2, wherein A is selected from the group consisting of
R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, alkoxy, alkyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, nitro, NRARB, NRARBC(O), NRARBC(O)alkyl and NRARBC(O)alkenyl;
R10 is selected from the group consisting of hydrogen and alkyl; and
R11 is independently selected from the group consisting of hydrogen, alkyl and arylalkyl.
4. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014.
5. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014; and
R8 is NRARB.
6. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014;
R8 is NRARB; and
R9A and R9B together are oxo.
7. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B))X2(CH2)pC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo; and
X2 is NRC.
8. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B))X2(CH2)pC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC; and
B is aryl.
9. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B))X2(CH2)pC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC;
B is aryl; and
A is
10. The compound according to claim 9, which is
N-5-({N-acetyl-4-(carboxycarbonyl)(2-carboxyphenyl)amino-3-ethylphenylalanyl}amino)pentanoyl-L-tyrosine.
11. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B))X2(CH2)pC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC; and
B is hydrogen.
12. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B))X2(CH2)pC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC;
B is hydrogen; and
A is
13. The compound according to claim 12, which is
N-5-({N-acetyl-4-(carboxycarbonyl)(2-carboxyphenyl)amino-3-ethylphenylalanyl}amino)pentanoyl-L-norleucine.
14. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pEC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014.
15. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pEC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014; and
R8 is NRARB.
16. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pEC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014;
R8 is NRARB; and
R9A and R9B together are oxo.
17. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pEC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo; and
X2 is NRC.
18. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pEC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC; and
B is hydrogen.
19. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R4)C(R9A)(R9B)X2(CH2)pEC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC;
B is hydrogen; and
E is cycloalkyl.
20. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pEC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC;
B is hydrogen;
E is cycloalkyl; and
A is
21. The compound according to claim 20, which is N-{4-({N-acetyl-4-(carboxycarbonyl)(2-carboxyphenyl)amino-3-(2-hydroxyethyl)phenylalanylamino}methyl)cyclohexylcarbonyl}-L-norleucine.
22. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B))X2(CH2)pC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC;
X3 is S; and
B is alkyl.
23. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B))X2(CH2)pC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC;
X3 is S;
B is alkyl; and
A is
24. The compound according to claim 23, selected from the group consisting of
N-{5-(N-acetyl-4-(carboxycarbonyl)(2-carboxyphenyl)amino-3-ethylphenylalanyl)aminopentanoyl}-L-methionine;
methyl N-{5-(N-acetyl-4-(carboxycarbonyl)(2-carboxyphenyl)amino-3-ethylphenylalanyl)aminopentanoyl}-L-methioninate;
N-{5-(N-acetyl-4-(carboxycarbonyl)(2-carboxyphenyl)amino-3-ethylphenylalanyl)aminopentanoyl}-S-ethyl-L-homocysteine;
N-{5-(N-acetyl-4-(carboxycarbonyl)(2-carboxyphenyl)amino-3-isopropylphenylalanyl)aminopentanoyl}-L-methionine;
N-{5-(N-acetyl-4-(carboxycarbonyl)(2-carboxy-5-chlorophenyl)amino-3-ethylphenylalanyl)aminopentanoyl}-L-methionine; and
N-(5-{N-acetyl-4-(carboxycarbonyl)(2-carboxyphenyl)amino-3-(2-hydroxyethyl)phenylalanylamino}pentanoyl)-L-methionine.
25. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B))X2(CH2)pC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC;
X3 is S; and
B is aryl.
26. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B))X2(CH2)pC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC;
X3 is S;
B is aryl; and
A is
27. The compound according to claim 26, which is
N-{5-(N-acetyl-4-(carboxycarbonyl)(2-carboxyphenyl)amino-3-ethylphenylalanyl)aminopentanoyl}-S-benzyl-L-cysteine.
28. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B))X2(CH2)pC(O)N(R10)CH(CO2R11)(CH2)qX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC;
X3 is S;
B is alkyl; and
A is
29. The compound according to claim 28, which is
N-(5-{3-(4-(carboxycarbonyl)(2-carboxyphenyl)amino-1-naphthyl)-N-(methoxycarbonyl)alanylamino}pentanoyl)-L-methionine.
30. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014.
31. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014; and
R8 is NRARB.
32. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is NRARB; and
R9A and R9B together are oxo.
33. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo; and
is NRC.
34. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC; and
X3 is O.
35. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(RB)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC;
X3 is O; and
B is aryl.
36. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC;
X3 is O;
B is aryl; and
A is
37. The compound according to claim 36, selected from the group consisting of
methyl 2-4-({N-(allyloxy)carbonyl-4-(carboxycarbonyl)(2-carboxyphenyl)amino-L-phenylalanyl}amino)butoxy-6-hydroxybenzoate;
methyl 2-{4-(N-acetyl-4-(carboxycarbonyl)(2-carboxyphenyl)amino-3-ethylphenylalanyl)aminobutoxy}-6-hydroxybenzoate;
methyl 4-{4-(N-acetyl-4-amino-3-ethylphenylalanyl)aminobutoxy}-2-hydroxy-1,1\u2032-biphenyl-3-carboxylate;
2-4-({N-acetyl-4-(carboxycarbonyl)(2-carboxyphenyl)amino-3-ethylphenylalanyl}amino)butoxy-6-hydroxybenzoic acid;
methyl 6-{4-(N-acetyl-4-(carboxycarbonyl)(2-carboxyphenyl)amino-3-ethylphenylalanyl)aminobutoxy}-3-bromo-2-hydroxybenzoate;
methyl 2-(4-{4-(carboxycarbonyl)(2-carboxyphenyl)amino-N-(methoxycarbonyl)-L-phenylalanylamino}butoxy)-6-hydroxy-4-pentylbenzoate;
methyl 2-(4-{4-(carboxycarbonyl)(2-carboxyphenyl)amino-N-(methoxycarbonyl)-L-phenylalanylamino}butoxy)-6-hydroxy-4-methoxybenzoate;
methyl 3-(4-{4-(carboxycarbonyl)(2-carboxyphenyl)amino-N-(methoxycarbonyl)-L-phenylalanylamino}butoxy)-5-hydroxy-1,1\u2032-biphenyl-4-carboxylate;
methyl 2-(4-{4-(carboxycarbonyl)(2-carboxyphenyl)amino-N-(methoxycarbonyl)-L-phenylalanylamino}butoxy)-6-hydroxy-4-methylbenzoate;
methyl 2-(4-{4-(carboxycarbonyl)(2-carboxyphenyl)amino-N-(methoxycarbonyl)-L-phenylalanylamino}butoxy)-4-chloro-6-hydroxybenzoate;
methyl 2-(4-{4-(carboxycarbonyl)(2-carboxyphenyl)amino-N-(methoxycarbonyl)-L-phenylalanylamino}butoxy)-6-hydroxybenzoate;
4-(carboxycarbonyl)(2-carboxyphenyl)amino-N-{4-2-(aminocarbonyl)-3-hydroxyphenoxybutyl}-N-(methoxycarbonyl)-L-phenylalaninamide;
methyl 3-(4-{4-(carboxycarbonyl)(2-carboxyphenyl)amino-N-(methoxycarbonyl)-L-phenylalanylamino}butoxy)-1-hydroxy-2-naphthoate;
4-(carboxycarbonyl)(2-carboxyphenyl)amino-N-(4-{3-hydroxy-2-(methylamino)carbonylphenoxy}butyl)-N-(methoxycarbonyl)-L-phenylalaninamide;
4-(carboxycarbonyl)(2-carboxyphenyl)amino-N-(4-{2-(ethylamino)carbonyl-3-hydroxyphenoxy}butyl)-N-(methoxycarbonyl)-L-phenylalaninamide;
N-{4-2-(acetylamino)-3-hydroxyphenoxybutyl}-4-(carboxycarbonyl)(2-carboxyphenyl)amino-N-(methoxycarbonyl)-L-phenylalaninamide; and
4-(carboxycarbonyl)(2-carboxyphenyl)amino-N-(4-{2-(dimethylamino)carbonyl-3-hydroxyphenoxy}butyl)-N-(methoxycarbonyl)-L-phenylalaninamide.
38. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC;
X3 is O;
B is aryl; and
A is
39. The compound according to claim 38, selected from the group consisting of
methyl 2-(5-{N-acetyl-3-(4-amino-1-naphthyl)-L-alanylamino}pentyl)oxy-6-hydroxy-4-methylbenzoate; and
3-({5-(N-acetyl-3-{4-(carboxycarbonyl)(2-carboxyphenyl)amino-1-naphthyl}-L-alanyl)aminopentyl}oxy)-2-naphthoic acid.
40. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014; and
R8 is hydrogen.
41. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is hydrogen; and
R9A and R9B together are oxo.
42. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is hydrogen;
R9A and R9B together are oxo; and
X2 is NRC.
43. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is hydrogen;
R9A and R9B together are oxo;
X2 is NRC; and
X3 is O.
44. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is hydrogen;
R9A and R9B together are oxo;
X2 is NRC;
X3 is O; and
B is aryl.
45. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is hydrogen;
R9A and R9B together are oxo;
X2 is NRC;
X3 is O; and
B is aryl; and
A is
46. The compound according to claim 45, which is
methyl 2-(4-{3-(4-(carboxycarbonyl)(2-carboxyphenyl)amino-3-ethylphenyl)propanoylamino}butoxy)-6-hydroxybenzoate.
47. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is hydrogen;
R9A and R9B together are oxo;
X2 is NRC;
X3 is O;
B is aryl; and
A is
48. The compound according to claim 47, which is
2-((carboxycarbonyl){4-3-({4-3-hydroxy-2-(methoxycarbonyl)phenoxybutyl}amino)-3-oxopropyl-(carboxycarbonyl)(2-carboxyphenyl)amino-1-naphthyl}amino)benzoic acid.
49. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is hydrogen; and
R9A is alkyl.
50. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is hydrogen;
R9A is alkyl; and
X2 is NRC.
51. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is hydrogen;
R9A is alkyl;
X2 is NRC; and
X3 is O.
52. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX 3\u2014;
R8 is hydrogen;
R9A is alkyl;
X2 is NRC;
X3 is O; and
B is aryl.
53. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is hydrogen;
R9A is alkyl;
X2 is NRC;
X3 is O;
B is aryl; and
A is
54. The compound according to claim 53, which is
methyl 2-(4-{3-(4-(carboxycarbonyl)(2-carboxyphenyl)amino-1-naphthyl)-1-methylpropylamino}butoxy)-6-hydroxybenzoate.
55. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is hydrogen; and
R9A and R9B are both hydrogen.
56. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is hydrogen;
R9A and R9B are both hydrogen; and
X2 is NRC.
57. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3;
R8 is hydrogen;
R9A and R9B are both hydrogen;
X2 is NRC; and
X3 is O.
58. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is hydrogen;
R9A and R9B are both hydrogen;
X2 is NRC;
X3 is O; and
B is aryl.
59. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3\u2014;
R8 is hydrogen;
R9A and R9B are both hydrogen;
X2 is NRC;
X3 is O;
B is aryl; and
A is
60. The compound according to claim 59, which is methyl 2-(4-{3-(4-(carboxycarbonyl)(2-carboxyphenyl)amino-1-naphthyl)propylamino}butoxy)-6-hydroxybenzoate.
61. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3(CH2)qX4\u2014.
62. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(RB)C(R9A)(R9B)X2(CH2)pX3(CH2)qX4\u2014; and
R8 is NRARB.
63. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3(CH2)qX4\u2014;
R8 is NRARB; and
R9A and R9B together are oxo.
64. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3(CH2)qX4\u2014;
R8 is NRARB;
R9A and R9B together are oxo; and
X2 is NRC.
65. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3(CH2)qX4\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC; and
X3 is O.
66. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3(CH2)qX4\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC;
X3 is O; and
X4 is O.
67. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3(CH2)qX4\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC;
X3 is O;
X4 is O; and
B is aryl.
68. The compound according to claim 2, wherein
L is \u2014(CH2)mX1(CH2)nCH(R8)C(R9A)(R9B)X2(CH2)pX3(CH2)qX4\u2014;
R8 is NRARB;
R9A and R9B together are oxo;
X2 is NRC;
X3 is O;
X4 is O;
B is aryl; and
A is
69. The compound according to claim 68, which is
methyl 2-{2-(2-({N-(allyloxy)carbonyl-4-(carboxycarbonyl)(2-carboxyphenyl)amino)-L-phenylalanyl}amino)ethoxyethoxy}-6-hydroxybenzoate.
70. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.
71. A method of treating diabetes by selectively inhibiting protein tyrosine phosphatase 1B comprising administering a therapeutically effective amount of a compound of claim 1.
72. A method of treating diabetes caused by overexpressed or altered protein tyrosine phosphatase 1B comprising administering a therapeutically effective amount of a compound of claim 1.